Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press143410.17650/1994-4098-2025-21-4-63-70MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИReview ArticleClinical and diagnostic features of lobular breast cancerКлинико-диагностические особенности долькового рака молочной железыhttps://orcid.org/0000-0001-8814-636XVysotskayaIrina V.ВысоцкаяИрина Викторовна
Russian Federation

Member of the RSOM Board, MD, PhD, Professor of the Department of Oncology

член правления РООМ, д.м.н., профессор кафедры онкологии

vysotnaya.irinavic63@gmail.comhttps://orcid.org/0000-0003-4893-8770KimE. A.КимЕ. А.
Russian Federation
vysotnaya.irinavic63@gmail.comhttps://orcid.org/0000-0003-2572-2547DenchikD. A.ДенчикД. А.
Russian Federation
vysotnaya.irinavic63@gmail.comhttps://orcid.org/0009-0001-9443-1244StrutsI. S.СтруцИ. С.
Russian Federation
vysotnaya.irinavic63@gmail.comhttps://orcid.org/0000-0003-2987-402XGolovinaE. A.ГоловинаЕ. А.
Russian Federation
vysotnaya.irinavic63@gmail.comhttps://orcid.org/0009-0005-5502-1524ShevkunovaA. V.ШевкуноваА. В.
Russian Federation
vysotnaya.irinavic63@gmail.comI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова (Сеченовский Университет) Минздрава РоссииN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииRostov State Medical University, Ministry of Health of RussiaФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России2001202621463702301202623012026Copyright ©; 2026, Vysotskaya I.V., Kim E.A., Denchik D.A., Struts I.S., Golovina E.A., Shevkunova A.V.Copyright ©; 2026, Высоцкая И.В., Ким Е.А., Денчик Д.А., Струц И.С., Головина Е.А., Шевкунова А.В.2026Vysotskaya I.V., Kim E.A., Denchik D.A., Struts I.S., Golovina E.A., Shevkunova A.V.Высоцкая И.В., Ким Е.А., Денчик Д.А., Струц И.С., Головина Е.А., Шевкунова А.В.https://creativecommons.org/licenses/by/4.0https://ojrs.abvpress.ru/ojrs/article/view/1434

This review focuses on current information regarding the clinical and diagnostic characteristics of lobular breast cancer. It presents information on the molecular biological characteristics and biological behavioral characteristics of various subtypes of preinvasive and infiltrative cancers of this histological type. Optimal treatment options for preinvasive and early invasive lobular breast cancer are identified.

Обзор посвящен современным данным, касающимся клинических и диагностических особенностей долькового рака молочной железы. Представлены сведения о молекулярно-биологических характеристиках и своеобразии биологического поведения различных подтипов преинвазивного и инфильтративного рака данного гистологического типа. Определены оптимальные варианты лечебной тактики при преинвазивном и начальном инвазивном дольковом раке молочной железы.

lobular carcinoma in situgenetic alterationmolecular subtype of lobular carcinomahistological typeimaging diagnosticsпреинвазивный дольковый ракгенетическое изменениемолекулярный подтип долькового ракагистологический типлучевая диагностикаArnold M., Morgan E., Rumgay H. et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 2022;66:15–23.McCart A.E., Kalinowski L., Simpson T. Invasive lobular carcinoma of the breast: the increasing importance of this distinct subtype. Breast Cancer Res 2021;23(1):6. DOI: 10.1186/S13058-020-01384-6Mukhtar R., Joe Chen A. Invasive lobular carcinoma of the breast: current trials, challenges, and future directions. Breast Cancer Upd Rep 2021;13:164–70.Kometova V.V. Breast Cancer Conference 2021. Available at: https://www.oncopathology.ru/sobytiya/event/rak-molochnoy-shelezi-2021/04-kometova-v-v-neinvazivniy-dolkoviy-rak-molochnoy-zhelezy-lcis.pdf. (In Russ.).Кометова В.В. Неинвазивный дольковый рак молочной железы. Конференция «Рак молочной железы», 2021. Доступно по: https://www.oncopathology.ru/sobytiya/event/rak-molochnoy-shelezi-2021/04-kometova-v-v-neinvazivniy-dolkoviy-rak-molochnoy-zhelezy-lcis.pdf.NCCN Guidelines Version 1/2021. Brest Cancer Screening and Diagnosis.Yadav S., Hu Ch., Nathanson K.L. Germline pathogenic variants in cancer susceptibility genes in women with invasive lobular breast carcinoma. 2021 J Clin Oncol 2021;39(35). DOI: 10.1200/JCO.21.00640Bidard F.K., Ng K.K., Cottu P. et al. Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. Ann Oncol 2015;26(8):1704–9.Yu J., da Silva E.M., La H.S. et al. Clinicopathologic and genomic features of lobular invasive breast carcinoma: is it a distinct entity? NPJ Breast Cancer 2023;9(1):60. DOI: 10.1038/s41523-023-00566-7Carbognin L., Simbolo M., Caglio A. et al. Targeted next-generation sequencing identifies genomic abnormalities potentially affecting prognosis in patients with early-stage invasive lobular breast carcinoma stratified according to a validated clinicopathologic model. Breast 2020;50:56–63. DOI: 10.1016/j.breast.2020.01.034Kurozumi S., Alsalim M., Monteiro S.J. et al. Targetable ERBB2 mutational status is an independent marker of poor prognosis in estrogen receptor-positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of publicly available datasets. Breast Cancer Res 2020;22(1):85. DOI: 10.1186/s13058-020-01324-4Nayyar U., Cohen O., Kapstad S. et al. Acquired HER2 mutations in ER(+) metastatic breast cancer confer resistance to estrogen receptor-targeted therapies. Nat Genet 2019;51(2):207–16. DOI: 10.1038/s41588-018-0287-5Berg W.A., Gutierrez L., NessAiver M.S. et al. Diagnostic accuracy of mammography, clinical examination, ultrasound, and MRI in the preoperative evaluation of breast cancer Radiology 2014;233:830–49.Hilleren D.J., Andersson I.T., Lindholm K. et al. Invasive lobular carcinoma: mammographic findings in a 10-year experience. Radiology 1991;178:149–54. DOI: 10.1148/radiology.178.1.1984294Costantini M., Montella R.A., Fadda M. et al. The diagnostic challenge of invasive lobular carcinoma of the breast: what’s in the news? Magnetic resonance imaging of the breast and the emerging role of contrast-enhanced spectral mammography. J Pers Med 2022;12(6):867. DOI: 10.3390/jpm12060867Lobbes M.B.I., Neeter L.M.F.H., Raat F. et al. Contrast-enhanced mammography and breast MRI in local preoperative staging of invasive lobular breast cancer. Eur J Radiol 2013;164:110881.Falk R.T., Maas P., Schairer C. et al. Alcohol and risk of breast cancer in postmenopausal women: an analysis of etiological heterogeneity by multiple tumor characteristics. Am J Epidemiol 2014;180:705–17. DOI: 10.1093/aje/kwu189Couto E., Sandin S., Löf M. et al. Mediterranean dietary pattern and risk of breast cancer. PLoS One 2013;8:e55374.Mouabbi J.A., Hassan A., Lim B. et al. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat 2022;193:253–64. DOI: 10.1007/s10549-022-06572-wYeh E.D., Slanetz P.J., Edmister W.B. et al. Invasive lobular carcinoma: enhancement spectrum and morphology on magnetic resonance imaging. Breast J 2003;9(1):13–8. DOI: 10.1046/j.1524-4741.2003.09104.x.Susnik B., Schneider L., Swenson K.K. et al. Prognostic value of breast magnetic resonance imaging in detecting mammographically occult contralateral breast cancer: can we target women with a higher likelihood of having contralateral breast cancer? J Surg Oncol 2018;118(1):221–7.Narbe U., Bendahl P.-O., Aaltonen K. et al. Distribution of circulating tumor cells differs in metastatic lobular carcinoma compared with ductal carcinoma of the breast – long-term prognostic implications. Cells 2020;9(7):1718. DOI: 10.3390/cells9071718Jones E.F., Hathi D.K., Freimanis R. et al. The current breast cancer imaging landscape and potential quantitative imaging markers of response in ER-positive breast cancer treated with neoadjuvant therapy. Cancers (Basel) 2020;12(6):1511. DOI: 10.3390/cancers12061511Ulaner G.A., Jhaveri K., Chardarlapati S. et al. Direct evaluation of 18F-FES and 18F-FDG PET/CT in metastatic invasive lobular breast cancer. J Nucl Med 2021;62(3):326–31. DOI: 10.2967/jnumed.120.247882Venema S., de Vries E., Glaudemans A. et al. 18F-FES PET has additional value in staging and therapeutic decisions in patients with disseminated lobular breast cancer. Clin Nucl Med 2017;42(8):612–4. DOI: 10.1097/RLU.0000000000001724